Nucleocapsid vaccine - EpicentRx
Alternative Names: Nucleocapsid vaccine-EpicentRxLatest Information Update: 28 Jul 2024
At a glance
- Originator EpicentRx
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 03 Aug 2022 Nucleocapsid vaccine - EpicentRx is available for licensing as of 08 Aug 2022. https://www.epicentrx.com/contact/
- 10 Jun 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) before June 2020